Non-Hodgkin Lymphoma News

• Change the 'Asymptomatic' Label for Rare Lymphoma Status Patients with a rare form of non-Hodgkin lymphoma who are followed with observation are labeled 'asymptomatic,' but they are rarely symptom free.
  Medscape Medical News, October 2019
• Family Members at Higher Risk for Blood Cancers First-degree relatives of a patient with blood cancer are at an increased risk of also being diagnosed, suggesting a shared etiology across hematologic malignancies.
  Medscape Medical News, September 2019
• Germany to Ban Use of Glyphosate From End of 2023 Germany will ban the use of the weedkiller glyphosate - the subject of billion-dollar U.S lawsuits over claims it causes cancer - from the end of 2023 and limit its use before then, the Environment Ministry said on Wednesday.
  Reuters Health Information, September 2019
• HIV: Underlying Infection Still Drives Deaths in US Life expectancy for US adults infected with HIV has risen dramatically since the early 1980s, but patients are still dying from HIV-related causes rather than age-related conditions.
  Medscape Medical News, September 2019
• Lithuanian PM Being Treated for Lymphoma, Will Keep Working Lithuanian Prime Minister Saulius Skvernelis said on Wednesday he had been diagnosed with early-stage lymphoma but would continue working while undergoing cancer treatment that was expected to run until early November.
  Reuters Health Information, August 2019
• Bayer Says Next Glyphosate Lawsuit Likely to Be Postponed Germany's Bayer said the next U.S. lawsuit scheduled to be heard over claims that its glyphosate-based weedkiller Roundup causes cancer would likely be postponed.
  Reuters Health Information, August 2019
• Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental Treatments Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations.
  Reuters Health Information, July 2019
• In Roundup Case, U.S. Judge Cuts $2 Billion Verdict Against Bayer to $86 Million A California judge on Thursday reduced a $2 billion jury verdict, slashing the award for a couple who blamed Bayer AG's glyphosate-based weed killer Roundup for their cancer to $86.7 million.
  Reuters Health Information, July 2019
• Pediatric Lymphoma Joins Family of BRCA2 Cancers Researchers call for genetic testing of all survivors of pediatric non-Hodgkin lymphoma after data revealed BRCA2 is implicated in the childhood disease.
  Medscape Medical News, July 2019
• Many Common, Deadly Cancers Underfunded by Nonprofits Many common, deadly cancers are underfunded by nonprofit organizations; these cancers affect parts of the body that are stigmatized, and this may be contributing, say researchers.
  Medscape Medical News, July 2019
• U.S. Judge to Slash $80 Million Roundup Jury Verdict-Court Hearing A U.S. judge on Tuesday said he would reduce an $80 million damage award against Bayer AG to $50 million or less in the case of a man who blamed his cancer on glyphosate-based weed killer Roundup.
  Reuters Health Information, July 2019
• Austrian Parliament Backs EU's First Total Ban of Weedkiller Glyphosate Austria's lower house of parliament passed a bill on Tuesday banning all uses of the weedkiller glyphosate, the first time a European Union country has taken such strong action against the chemical over concerns that it can cause cancer.
  Reuters Health Information, July 2019
• IWMF 2019Living Harmoniously With Incurable Cancer Diagnosed with cancer at age 44, Lise Wise hesitated to go to the support meeting recommended to her because she expected to find sick people who had no hair and no eyebrows, but she found more.
  Medscape Medical News, June 2019
• IWMF 2019Lymphoma Control Better Goal Than Remission Drugs used to treat lymphoplasmacytic lymphoma can have adverse effects, so lowering therapeutic targets might help, delegates heard at the International Waldenstrom's Macroglobulinemia Forum.
  Medscape Medical News, June 2019
• EHA 2019Novel Drug Targets Lymphoma Cells' 'Don't Eat Me' Signal The first-in-class agent Hu5F9 is a macrophage immune checkpoint inhibitor and, when added onto rituximab, shows potentially long-lasting efficacy in patients with relapsed and refractory lymphoma.
  Medscape Medical News, June 2019
• IWMF 2019New Lymphoma Drugs Build on BTK Inhibitor Success Life expectancy for patients with Waldenstrom's macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.
  Medscape Medical News, May 2019
• IWMF 2019Patients With Rare Lymphoma Describe Divergent Experiences Some people are treated aggressively while others watch and wait until symptoms appear; three will describe their experiences at the upcoming Waldenstrom's Macroglobulinemia forum.
  Medscape Medical News, May 2019
• Cemiplimab and Talazoparib Head Toward Approval in the EU Both drugs have received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use, which is the first step in obtaining marketing approval in the European Union.
  International Approvals, April 2019
• Novel CAR T-Cell Approach Reduces Toxicities, Retains Efficacy The modified molecule for the anti-CD19 CAR T-cell therapy shows signs of reducing the risk for severe cytokine release syndrome while maintaining efficacy.
  Medscape Medical News, April 2019
• For Rare, Difficult Cancer, New Drug Is a 'Major Advance' Tagraxofusp, the first-ever drug for blastic plasmacytoid dendritic-cell neoplasm, is being called a major advance. Data are now published in the New England Journal of Medicine.
  Medscape Medical News, April 2019